Evidence map›Paper›PMID 21978382›Full record

Trial reportTrials2011

Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial.

Seok-Jae Ko, Bongha Ryu, Jinsung Kim, Beom-Gi Hong, Inkwon Yeo, Beom-Joon Lee, Jin-Moo Lee, Jae-Woo Park

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Effect ofFood science & nutrition · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Nitrate Is Crucial for the Proliferation of GutFrontiers in microbiology · 2020
    Article
  6. Article
  7. Role of Gut Microbiota in the Pharmacological Effects of Natural Products.Evidence-based complementary and alternative medicine : eCAM · 2019
    Review
  8. Article
  9. Evaluating the efficacy of mixture ofJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Seok-Jae KoDepartment of Internal Medicine, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.
Bongha Ryu
Jinsung Kim
Beom-Gi Hong
Inkwon Yeo
Beom-Joon Lee
Jin-Moo Lee
Jae-Woo Park
Kyung Hee University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS. METHODS/

designThe current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a 2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10 weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks). DISCUSSION: The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS.

Indexed as

Clinical ProtocolsAdolescentAdultAgedDiarrheaDouble-Blind MethodHumansIntestinal MucosaIntestinesIrritable Bowel SyndromeMiddle AgedOutcome Assessment, Health CarePermeabilityPlant ExtractsProbioticsPlant Extracts

Identifiers

PMID21978382
PMCPMC3198690
OpenAlexW2163097656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.